First-in-man Implantation of the XINSORB Bioresorbable Sirolimus-eluting Scaffold in China  

作　　者：Jia-Hui Chen Yi-Zhe Wu Li Shen Feng Zhang Zhi-Feng Yao Jia-Sheng Yin Meng Ji Qi-Bing Wang Lei Ge Ju-Ying Qian Xi Hu Jian Xie Jun-Bo Ge 

机构地区：[1]Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China [2]Shanghai Weite Biotechnology Co. Ltd., Shanghai 201203, China

出　　处：《Chinese Medical Journal》2015年第9期1275-1276,共2页中华医学杂志（英文版）

基　　金：a grant from National Natural Science Foundation of China，the National Basic Research Program of China （No.2011CB503905） from the Ministry of Science and Technology of China,the Specialized Research Fund for the Doctoral Program of Higher Education of China，the Science and Technology Commission of Shanghai,China （No.12DZ1940604）.Conflict of Interest：None

摘　　要：To the Editor：A 35-year-old man who smoked for 15 years suffered from chest pain 12 days ago before admission.He was diagnosed as myocardial infarction.Thrombolytic therapy was given consequently.The electrocardiogram showed sub-acute inferior wall myocardial infarction.Echocardiogram showed attenuated constriction of the inferior wall with an ejection fraction of 59％.On September 5,2013,he was treated with a XINSORB scaffold in right coronary artery （RCA）.To the Editor：A 35-year-old man who smoked for 15 years suffered from chest pain 12 days ago before admission.He was diagnosed as myocardial infarction.Thrombolytic therapy was given consequently.The electrocardiogram showed sub-acute inferior wall myocardial infarction.Echocardiogram showed attenuated constriction of the inferior wall with an ejection fraction of 59％.On September 5,2013,he was treated with a XINSORB scaffold in right coronary artery （RCA）.

分 类 号：Q492.6[生物学—生理学] TQ465.5[化学工程—制药化工]